Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Natalizumab Use During the Third Trimester of Pregnancy.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Analysis: Healthy babies born after accelerated elimination of teriflunomide
Saccadic intrusions: review and update.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Genzyme's Lemtrada resubmission accepted for review by FDA
Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
Biogen Reports Another Tecfidera PML Case
Determination and characterization of a cannabinoid receptor in rat brain.
PI(3,5)P2 biosynthesis regulates oligodendrocyte differentiation by intrinsic and extrinsic mechanisms.
A high-density screen for linkage in multiple sclerosis.
Vitamin D intake and incidence of multiple sclerosis.
Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Physiopathological Roles of p2x Receptors in the Central Nervous System.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.

Pages